Bionik Laboratories logo

Bionik Laboratories(OTC) BNKL

Market Cap$1.20KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2015)-100%
5 Year-100%
1 Year+0%
1 Month+0%
$0.00
+0.00%
+0.00Today
Bionik Laboratories last closing stock price
MetricPriceDate
Last closeUSD 0.002026-09-29
Bionik Laboratories stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-09-04
1 month+0%USD 0.002026-05-27
3 month+0%USD 0.002026-05-27
Year to date+9,900%USD 0.002025-12-24
1 year+0%USD 0.002025-09-23
3 year-99.96%USD 0.242023-09-26
5 year-99.99%USD 1.412021-09-30
Since inception-100%USD 330.032015-03-05

Bionik Laboratories Financials at a Glance

Market Cap

$1.20KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$1.81M

Net Income (TTM)

-$5.07M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

945.93 (High)

Price

$0.00

Volume

7

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Feb 6, 2024

BNKL News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Bionik Laboratories

Bionik Laboratories Corp. is a robotics firm dedicated to the innovation and development of advanced solutions for physical rehabilitation, prosthetic devices, and assistive robotics. The company offers a range of products designed to enhance therapeutic outcomes and improve patient mobility.

Products and Services
  • InMotion Robots, a collection of robotic therapy tools
  • InMotion ARM, an interactive therapeutic system for patient movement
  • InMotion Connect platform, integrating hardware and subscription services
Growth Outlook
  • Focus on expanding product offerings in rehabilitation technology
  • Increasing demand for assistive robotics in healthcare settings
  • Potential partnerships with healthcare providers to enhance market reach
Financial Highlights
  • Recent quarterly revenue of 501,114, showing a slight decrease from previous quarter
  • Trailing twelve months (TTM) gross profit margin at 50.7%, indicating strong product demand
  • Current ratio of 1.20, suggesting adequate short-term financial health
Bionik Laboratories Corp. operates in the healthcare sector, specifically within medical care facilities, and is focused on enhancing rehabilitation through innovative robotic solutions. The company's flagship products, including the InMotion Robots, are designed to provide interactive and evidence-based therapy, which is crucial for patient recovery. The growth outlook for Bionik Laboratories is promising, driven by an increasing demand for advanced rehabilitation technologies and potential collaborations with healthcare providers. This could lead to expanded market opportunities and enhanced product offerings. Financially, the company reported a recent quarterly revenue of 501,114, reflecting a slight decrease compared to the previous quarter. However, the gross profit margin remains robust at 50.7%, indicating a solid demand for its products. The current ratio of 1.20 suggests that the company is in a stable position to meet its short-term obligations, which is a positive indicator for potential investors. Overall, Bionik Laboratories Corp. presents an intriguing opportunity in the healthcare technology space, with a focus on innovative solutions that address critical rehabilitation needs.
AI Generated • Sep 11, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

13

CEO

Richard Russo, Jr., CPA

Website

www.bioniklabs.com

Headquarters

Watertown, MA 02472, US

BNKL Financials

Key Financial Metrics (TTM)

Gross Margin

54.83%

Operating Margin

-267.29%

Net Income Margin

-273.99%

Return on Equity

-768.84%

Return on Capital

-625.23%

Return on Assets

-147.11%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.20KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

12.48M

Volume

7

Avg. Volume

0.154

Financials (TTM)

Gross Profit

$989.88K

Operating Income

-$4.83M

EBITDA

-$4.78M

Operating Cash Flow

-$3.39M

Capital Expenditure

$99.57K

Free Cash Flow

-$3.29M

Cash & ST Invst.

$427.38K

Total Debt

$2.41M

Bionik Laboratories Performance Analysis

Bionik Laboratories annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-03-31USD 1,273,712N/A
20232023-03-31USD 1,805,20241.7%
Bionik Laboratories sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12022-06-3027.0%
Q22022-09-30100.2%
Q32022-12-3118.3%
Q42023-03-31-12.9%
Bionik Laboratories annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-03-31USD -1.78N/A
20232023-03-31USD -0.72-59.8%
Bionik Laboratories sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12022-06-3041.2%
Q22022-09-3015.0%
Q32022-12-315.9%
Q42023-03-31-25.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2023YOY CHG

Revenue

$501.11K

+162.0%

Gross Profit

$254.12K

+91.6%

Gross Margin

50.71%

N/A

Market Cap

$1.20KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$100.00

N/A

Employees

12

N/A

Net Income

-$1.42M

+29.6%

EBITDA

-$1.28M

+11.2%

Quarterly Fundamentals

Name
Q4 2023YOY CHG

Total Cash

$427.38K

-78.5%

Total Debt

$2.41M

N/A

Accounts Receivable

$453.08K

+64.9%

Inventory

$1.03M

-13.1%

Long Term Debt

$2.39M

N/A

Short Term Debt

$22.07K

N/A

Return on Assets

-1.47%

N/A

Return on Invested Capital

-4.58%

N/A

Free Cash Flow

-$757.70K

+45.1%

Operating Cash Flow

-$756.94K

+45.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
FSPMFusionPharm, Inc.
$0.00+0.00%
BGMDBG Medicine, Inc.
$0.00+0.00%
OHAQOracle Healthcare Acquisition Corp.
$0.00+0.00%
NMTRQ9 Meters Biopharma, Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$113.12+0.55%
NUNu Holdings
$15.58-0.51%
NVDANvidia
$237.47-0.74%
BULLWebull
$5.89-19.09%

Questions About BNKL

What is the current price of Bionik Laboratories?

Bionik Laboratories is trading at $0.00 per share.

What is the 52-week range for Bionik Laboratories?

Over the past 52 weeks, Bionik Laboratories has traded between $0.00 and $0.00.

How much debt does Bionik Laboratories have?

As of the most recent reporting period, Bionik Laboratories reported total debt of $2.41M.

How much cash does Bionik Laboratories have on hand?

Bionik Laboratories reported $427.38K in cash and cash equivalents in its most recent financial results.

What is Bionik Laboratories’s dividend yield?

Bionik Laboratories does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services